Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2024 07:59 ET | Source: Pasithea

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Pasithea Therapeutics' PAS-004 abstract accepted for ASCO poster presentation: novel MEK inhibitor shows promise for NF1 and cancer therapy.
November 01, 2023 02:20 ET | Source: Spexis AG

Spexis Announces Changes to the Executive Committee

Spexis Announces Changes to the Executive Committee
October 06, 2023 01:30 ET | Source: Spexis AG

Spexis to host business update conference call on October 9, 2023

Spexis to host business update conference call on October 9, 2023
September 29, 2023 01:30 ET | Source: Spexis AG

Spexis provides business update and announces financial results for the first half of 2023

Spexis provides business update and announces financial results for the first half of 2023
September 28, 2023 01:30 ET | Source: Spexis AG

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
August 15, 2023 01:15 ET | Source: Spexis AG

Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies

Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle...
June 30, 2023 01:15 ET | Source: Spexis AG

Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions

Ad hoc announcement pursuant to Art. 53 LR ALLSCHWIL, Switzerland, June 29, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and...
June 07, 2023 01:15 ET | Source: Spexis AG

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains

ALLSCHWIL, Switzerland, June 06, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced the publication of...